ECSP20008441A - Dihidrooxadiazinonas - Google Patents
DihidrooxadiazinonasInfo
- Publication number
- ECSP20008441A ECSP20008441A ECSENADI20208441A ECDI202008441A ECSP20008441A EC SP20008441 A ECSP20008441 A EC SP20008441A EC SENADI20208441 A ECSENADI20208441 A EC SENADI20208441A EC DI202008441 A ECDI202008441 A EC DI202008441A EC SP20008441 A ECSP20008441 A EC SP20008441A
- Authority
- EC
- Ecuador
- Prior art keywords
- compounds
- preparation
- pharmaceutical compositions
- diseases
- dihydrooxadiazinones
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
- C07D273/04—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Catalysts (AREA)
Abstract
La invención proporciona compuestos de dihidrooxidiazinona de la fórmula general (I): en donde R1, R2, R3, y R4 son como se definen en el presente, procedimientos para la preparación de dichos compuestos, compuestos intermedios útiles para la preparación de dichos compuestos, composiciones farmacéuticas y combinaciones que comprenden dichos compuestos y el uso de dichos compuestos para la elaboración de composiciones farmacéuticas para el tratamiento o la profilaxis de enfermedades, en especial de enfermedades hiperproliferativas, como un único agente o en combinación con otros ingredientes activos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762541627P | 2017-08-04 | 2017-08-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP20008441A true ECSP20008441A (es) | 2020-05-29 |
Family
ID=63207725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI20208441A ECSP20008441A (es) | 2017-08-04 | 2020-02-04 | Dihidrooxadiazinonas |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US11427553B2 (es) |
| EP (1) | EP3661517B1 (es) |
| JP (2) | JP7676141B2 (es) |
| KR (1) | KR20200036914A (es) |
| CN (1) | CN111212647B (es) |
| AR (1) | AR112402A1 (es) |
| AU (1) | AU2018309356B2 (es) |
| BR (1) | BR112020002351A2 (es) |
| CA (1) | CA3071800A1 (es) |
| CL (1) | CL2020000303A1 (es) |
| CO (1) | CO2020001242A2 (es) |
| CR (1) | CR20200057A (es) |
| CU (1) | CU24608B1 (es) |
| EA (1) | EA202090448A1 (es) |
| EC (1) | ECSP20008441A (es) |
| IL (1) | IL272098B2 (es) |
| JO (1) | JOP20200024A1 (es) |
| MA (1) | MA49750A (es) |
| MX (1) | MX2020001404A (es) |
| PE (1) | PE20200936A1 (es) |
| PH (1) | PH12020500134A1 (es) |
| SG (1) | SG11201913775UA (es) |
| TW (1) | TWI791581B (es) |
| UA (1) | UA125731C2 (es) |
| UY (1) | UY37832A (es) |
| WO (1) | WO2019025562A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11897867B2 (en) | 2017-08-04 | 2024-02-13 | Bayer Aktiengesellschaft | 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives as PDE3A and PDE3B inhibitors for treating cancer |
| JOP20200024A1 (ar) | 2017-08-04 | 2020-02-02 | Bayer Ag | مركبات ثنائي هيدروكساديازينون |
| WO2020092998A1 (en) | 2018-11-01 | 2020-05-07 | The Broad Institute, Inc. | Identification of pde3 modulator responsive cancers |
| WO2020157188A1 (en) * | 2019-02-01 | 2020-08-06 | Bayer Aktiengesellschaft | Dihydrooxadiazinones for the treatment of hyperproliferative diseases |
| AU2020215088A1 (en) | 2019-02-01 | 2021-07-22 | Bayer Aktiengesellschaft | 1,2,4-triazin-3(2H)-one compounds for the treatment of hyperproliferative diseases |
| JP2024508171A (ja) | 2021-03-03 | 2024-02-22 | バイエル アクチェンゲゼルシャフト | 肉腫の処置のための置換３，６－ジヒドロ－２ｈ－１，３，４－オキサジアジン－２－オン |
| EP4289829A1 (en) | 2022-06-10 | 2023-12-13 | Bayer Aktiengesellschaft | Crystalline forms of (6s)-5-[4'-fluoro-2-(trifluoromethyl)biphenyl-4-yl]-6-methyl-3,6-dihydro- 2h-1,3,4-oxadiazin-2-one |
| EP4289828A1 (en) | 2022-06-10 | 2023-12-13 | Bayer Aktiengesellschaft | Method for the preparation of a 3,6-dihydro-2h-1,3,4-oxadiazin-2-one |
| CN120187704A (zh) * | 2022-11-24 | 2025-06-20 | 盛睿泽华医药科技（苏州）有限公司 | 吡啶酮化合物及其制备方法和用途 |
| CN117903077B (zh) * | 2023-01-13 | 2024-09-03 | 上海超阳药业有限公司 | 二氢噁二嗪酮化合物及其应用 |
| CN118420559B (zh) * | 2023-04-27 | 2025-02-14 | 上海超阳药业有限公司 | 氘代噁二嗪酮化合物及其用途 |
| CN118047833B (zh) * | 2024-01-31 | 2025-03-14 | 海南大学 | 含二茂铁的取代氨基乙酰胺类化合物及其制备方法和应用 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4097671A (en) * | 1975-08-28 | 1978-06-27 | General Electric Company | Dihydrooxadiazinones and method for making |
| US4052395A (en) | 1975-09-11 | 1977-10-04 | Sankyo Company Limited | Agricultural fungicidal compositions containing 6-(substituted phenyl)-pyridazinones and said pyridazinones |
| US4258094A (en) * | 1979-04-26 | 1981-03-24 | Brunswick Corporation | Melt bonded fabrics and a method for their production |
| US4334030A (en) | 1979-11-23 | 1982-06-08 | General Electric Company | Thermoplastic foamable blends |
| EP0052442B1 (en) | 1980-11-14 | 1985-09-11 | Imperial Chemical Industries Plc | Heterocyclic compounds |
| ATE13294T1 (de) | 1981-03-04 | 1985-06-15 | Ciba Geigy Ag | Pyridazinone, verfahren zu ihrer herstellung, pharmazeutische praeparate enthaltend diese verbindungen und deren verwendung. |
| US4495185A (en) | 1981-11-12 | 1985-01-22 | Imperial Chemical Industries, Plc | 1,2,4-Triazin-3(2H) ones |
| ZA827641B (en) | 1981-11-12 | 1983-09-28 | Ici Plc | Thiadiazine, oxadiazine and triazine derivatives which possess cardiotonic and/or antihypertensive activity |
| US4581356A (en) | 1983-03-22 | 1986-04-08 | Fujisawa Pharmaceutical Co., Ltd. | Triazine derivatives, and pharmaceutical compositions comprising the same |
| GB8310435D0 (en) | 1983-04-18 | 1983-05-25 | Fujisawa Pharmaceutical Co | Triazine derivatives |
| JPS59196874A (ja) | 1983-04-22 | 1984-11-08 | Fujisawa Pharmaceut Co Ltd | トリアジン誘導体 |
| JPS6153270A (ja) | 1984-08-17 | 1986-03-17 | チバ・ガイギー・アクチエンゲゼルシヤフト | 置換ピリダジノン、その製造方法及び該化合物を含む医薬製剤 |
| US4816454A (en) | 1984-09-21 | 1989-03-28 | Cassella Aktiengesellschaft | 4,5-dihydro-3(2H)-pyridazinones and their pharmacological use |
| GB8426804D0 (en) | 1984-10-23 | 1984-11-28 | Ciba Geigy Ag | Pyridazinones preparations |
| ZW20586A1 (en) | 1985-10-17 | 1988-05-25 | Smith Kline French Lab | Chemical compounds |
| EP0303418A3 (en) | 1987-08-11 | 1990-11-07 | Smithkline Beecham Laboratoires Pharmaceutiques | Substituted indolones, useful in the treatment of heart or asthmatic diseases |
| EP0478195B1 (en) | 1990-09-21 | 1999-05-26 | Rohm And Haas Company | Dihydropyridazinones and pyridazinones as fungicides |
| JPH0676325B2 (ja) * | 1992-05-08 | 1994-09-28 | 三井東圧化学株式会社 | オキサジアジン誘導体を有効成分として含有する抗血栓剤 |
| NZ254534A (en) | 1992-07-01 | 1997-12-19 | Ortho Pharma Corp | 1,4,5,6-tetrahydro-pyridazine derivatives, preparation and pharmaceutical compositions thereof |
| JPH07291968A (ja) | 1994-04-26 | 1995-11-07 | Mitsubishi Chem Corp | トリアジノン誘導体またはその塩類 |
| DE19929787A1 (de) * | 1999-06-29 | 2001-01-04 | Bayer Ag | Neue 4-(2-Oxodihydrooxadiazinylphenyl)amide und ihre Verwendung |
| WO2002072103A1 (en) * | 2001-02-12 | 2002-09-19 | Merck Patent Gmbh | Use of type 4 phosphodiesterase inhibitors in myocardial diseases |
| WO2008108602A1 (en) | 2007-03-07 | 2008-09-12 | Dong-A Pharm. Co., Ltd. | Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same |
| CN101538245B (zh) | 2008-03-18 | 2011-02-16 | 中国科学院上海药物研究所 | 一类哒嗪酮类化合物及其制备方法和制备药物的用途 |
| US9212146B2 (en) | 2008-03-18 | 2015-12-15 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Substituted pyridazinones for the treatment of tumors |
| JP5711724B2 (ja) | 2009-04-15 | 2015-05-07 | リサーチ・トライアングル・インスティチュート | モノアミン再取り込み阻害剤 |
| FR2948940B1 (fr) * | 2009-08-04 | 2011-07-22 | Servier Lab | Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP2566864B1 (en) | 2010-05-07 | 2014-09-03 | Boehringer Ingelheim International GmbH | Pyridazinones as gpr119 agonists |
| EP2675440B1 (en) | 2011-02-14 | 2020-03-25 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| TWI532742B (zh) | 2011-02-28 | 2016-05-11 | 艾伯維有限公司 | 激酶之三環抑制劑 |
| US9890127B2 (en) * | 2013-03-11 | 2018-02-13 | The Broad Institute, Inc. | Compounds and compositions for the treatment of cancer |
| TWI700283B (zh) | 2014-08-04 | 2020-08-01 | 德商拜耳製藥公司 | ２-(嗎啉-４-基)-１,７-萘啶 |
| CA2995375C (en) | 2015-08-13 | 2024-06-18 | The Broad Institute, Inc. | Compositions and methods for cancer expressing pde3a or slfn12 |
| WO2017121684A1 (en) | 2016-01-14 | 2017-07-20 | Bayer Pharma Aktiengesellschaft | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines |
| EP3411037B1 (en) | 2016-02-05 | 2021-10-20 | Bayer Pharma Aktiengesellschaft | Compounds, compositions and methods for cancer patient stratification and cancer treatment |
| KR101831772B1 (ko) * | 2016-03-24 | 2018-03-06 | 아이디에스(주) | 복합 광원 모듈을 가지는 카메라 접사용 기구 및 이를 이용한 지문 시편 촬영 방법 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| US11897867B2 (en) | 2017-08-04 | 2024-02-13 | Bayer Aktiengesellschaft | 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives as PDE3A and PDE3B inhibitors for treating cancer |
| JOP20200024A1 (ar) | 2017-08-04 | 2020-02-02 | Bayer Ag | مركبات ثنائي هيدروكساديازينون |
| WO2020092998A1 (en) | 2018-11-01 | 2020-05-07 | The Broad Institute, Inc. | Identification of pde3 modulator responsive cancers |
| AU2020215088A1 (en) | 2019-02-01 | 2021-07-22 | Bayer Aktiengesellschaft | 1,2,4-triazin-3(2H)-one compounds for the treatment of hyperproliferative diseases |
-
2018
- 2018-08-01 JO JOP/2020/0024A patent/JOP20200024A1/ar unknown
- 2018-08-02 CA CA3071800A patent/CA3071800A1/en active Pending
- 2018-08-02 PE PE2020000184A patent/PE20200936A1/es unknown
- 2018-08-02 UA UAA202001558A patent/UA125731C2/uk unknown
- 2018-08-02 US US16/635,504 patent/US11427553B2/en active Active
- 2018-08-02 CU CU2020000008A patent/CU24608B1/es unknown
- 2018-08-02 EA EA202090448A patent/EA202090448A1/ru unknown
- 2018-08-02 SG SG11201913775UA patent/SG11201913775UA/en unknown
- 2018-08-02 AU AU2018309356A patent/AU2018309356B2/en not_active Ceased
- 2018-08-02 MX MX2020001404A patent/MX2020001404A/es unknown
- 2018-08-02 MA MA049750A patent/MA49750A/fr unknown
- 2018-08-02 JP JP2020505898A patent/JP7676141B2/ja active Active
- 2018-08-02 EP EP18755153.6A patent/EP3661517B1/en active Active
- 2018-08-02 CN CN201880050751.0A patent/CN111212647B/zh active Active
- 2018-08-02 WO PCT/EP2018/071039 patent/WO2019025562A1/en not_active Ceased
- 2018-08-02 CR CR20200057A patent/CR20200057A/es unknown
- 2018-08-02 BR BR112020002351-5A patent/BR112020002351A2/pt not_active IP Right Cessation
- 2018-08-02 KR KR1020207005998A patent/KR20200036914A/ko not_active Withdrawn
- 2018-08-03 TW TW107127172A patent/TWI791581B/zh not_active IP Right Cessation
- 2018-08-03 UY UY0001037832A patent/UY37832A/es not_active Application Discontinuation
- 2018-08-03 AR ARP180102218 patent/AR112402A1/es not_active Application Discontinuation
-
2020
- 2020-01-16 IL IL272098A patent/IL272098B2/en unknown
- 2020-01-17 PH PH12020500134A patent/PH12020500134A1/en unknown
- 2020-02-04 EC ECSENADI20208441A patent/ECSP20008441A/es unknown
- 2020-02-04 CO CONC2020/0001242A patent/CO2020001242A2/es unknown
- 2020-02-04 CL CL2020000303A patent/CL2020000303A1/es unknown
-
2022
- 2022-07-11 US US17/862,255 patent/US12258323B2/en active Active
- 2022-07-14 US US17/865,236 patent/US11773070B2/en active Active
-
2023
- 2023-06-13 JP JP2023097166A patent/JP2023115065A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20008441A (es) | Dihidrooxadiazinonas | |
| ECSP19030002A (es) | 1,2,4-triazolonas 2,4,5-trisustituidas | |
| CO2018010966A2 (es) | Nuevos derivados de pirazolopirimidina | |
| DOP2020000023A (es) | Nuevos derivados de quinolina | |
| DOP2019000117A (es) | Nuevos derivados de quinolina | |
| CO2019014484A2 (es) | Nuevos derivados de azaquinolina | |
| UY37460A (es) | 1,2,4-triazolonas con anelación en 4 y 5 | |
| CL2021001042A1 (es) | Nuevos compuestos antihelmínticos | |
| CO2020013876A2 (es) | Nuevos derivados de quinolina | |
| CO2019011877A2 (es) | Nuevos derivados de pirazol bicíclicos | |
| DOP2019000206A (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas | |
| UY37971A (es) | Derivados de indol macrocíclicos sustituidos | |
| UY38816A (es) | Nuevos derivados de isoquinolina | |
| UY37973A (es) | Derivados de indol macrocíclicos | |
| DOP2020000100A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
| UY37972A (es) | Derivados de indol macrocíclicos sustituidos con cloro | |
| UY36983A (es) | Pirazolopiridinaminas sustituidas | |
| UY37032A (es) | Compuestos de heteroarilbenzimidazol |